GenFleet Therapeutics (Shanghai) Inc. (GENFLEET-B) disclosed a share buyback executed on 28 September 2026 under its existing repurchase mandate approved on 11 May 2026.
Key transaction details: • Volume and pricing: 116,000 H-shares were repurchased on the Hong Kong Stock Exchange at prices ranging from HKD 26.98 to HKD 27.96, with a volume-weighted average cost of HKD 27.4612 per share. The aggregate consideration amounted to HKD 3.19 million. • Capital structure impact: Issued shares (excluding treasury shares) declined by 0.033% to 350.64 million. Treasury shares increased from 872,000 to 988,000, while total issued shares remained unchanged at 351.63 million. • Mandate utilisation: Cumulative buybacks under the current mandate now total 988,000 shares, representing 0.27% of the 370.37 million shares authorised for repurchase. • Post-buyback restrictions: In line with Hong Kong Listing Rules, GenFleet is subject to a moratorium on new share issues or sales of treasury shares until 28 October 2026.
All repurchases were conducted on-market and confirmed to be in full compliance with Hong Kong Stock Exchange regulations and relevant legal requirements.